• ZDHHC2 Drives Selective RAF Degradation in TB-Infected Macro

  2026-05-09

  This study uncovers how the palmitoyltransferase ZDHHC2 selectively drives autophagic degradation of B-RAF and C-RAF, enhancing antimycobacterial responses in macrophages. The work identifies ZDHHC2 as a critical regulator of ERK pathway activity during Mycobacterium tuberculosis infection, offering new mechanistic insight and potential therapeutic targets.

• Erastin and the Ferroptosis Frontier: Precision Tools for Tr

  2026-05-09

  This thought-leadership article explores the mechanistic nuances and strategic applications of Erastin, a potent ferroptosis inducer, as a precision tool in cancer biology research. By integrating insights from the latest glioblastoma studies and competitive benchmarks, we guide translational researchers through experimental design, protocol optimization, and the evolving landscape of ferroptosis-targeted interventions.

• Neuroimaging Dopaminergic Neuron Maturation in PD Models

  2026-05-08

  Goggi et al. (2020) demonstrate that dopamine transporter (DAT) neuroimaging enables precise, non-invasive assessment of human embryonic stem cell-derived dopaminergic neuron maturation in preclinical Parkinson’s disease models. Their findings establish DAT-PET as a sensitive tool for tracking graft survival and functional integration, with implications for evaluating cell-based therapies and optimizing translational research protocols.

• Comparative Metabolic Profiling of Tiamulin in Farm Animals

  2026-05-07

  This study provides a comprehensive metabolic analysis of Tiamulin (Thiamutilin) across multiple farm animal species, employing UHPLC-Q/TOF to identify 26 metabolites, many for the first time. The findings clarify interspecies differences in drug metabolism and inform residue monitoring strategies, supporting both food safety and rational veterinary antibiotic use.

• Epalrestat: Aldose Reductase Inhibitor for Translational Met

  2026-05-07

  Epalrestat from APExBIO stands out as a high-purity aldose reductase inhibitor, enabling precise investigation of the polyol pathway in diabetic neuropathy, neuroprotection, and cancer metabolism. This article details advanced protocols, experimental troubleshooting, and practical insights for leveraging Epalrestat in oxidative stress and polyol pathway inhibition research.

• Rhodamine B in Environmental & Cell Imaging: Protocol Advanc

  2026-05-06

  Rhodamine B (Basic Violet 10) is redefining both environmental tracer studies and cell labeling workflows with its high solubility, robust fluorescence, and batch-to-batch purity. This article delivers actionable protocols, comparative evidence, and troubleshooting strategies to help researchers maximize reproducibility and sensitivity across cross-disciplinary applications.

• Dimethyloxalylglycine (DMOG): Technical Parameters & Workflo

  2026-05-06

  Dimethyloxalylglycine (DMOG) enables researchers to simulate hypoxic conditions by stabilizing hypoxia-inducible factors (HIFs) in cell and animal models. It should be used strictly in preclinical research, not for diagnostic or therapeutic purposes. Precise attention to solubility, storage, and workflow controls is essential to ensure reproducible and interpretable results.

• BMN 673 (Talazoparib): Precision Tools for DNA Repair Defici

  2026-05-05

  Explore how BMN 673 (Talazoparib) is revolutionizing DNA repair deficiency targeting with unmatched selectivity. This article uniquely dissects the latest mechanistic insights and practical assay considerations for researchers using PARP inhibitors in homologous recombination deficient cancer models.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-05-05

  This study reveals that specific angiotensin peptides, particularly truncated forms of angiotensin II, significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor, advancing the understanding of host-virus interactions. The findings highlight implications for COVID-19 pathogenesis and suggest new angles for therapeutic targeting within the renin-angiotensin system.

• BGJ398 (NVP-BGJ398): Optimized Workflows for FGFR Signaling

  2026-05-04

  BGJ398 (NVP-BGJ398) empowers precise inhibition of FGFR1/2/3, enabling advanced oncology and developmental biology assays. This article delivers practical protocols, troubleshooting insights, and workflow enhancements for reproducible results in FGFR-driven malignancies research.

• Catalpol’s Multi-Pathway Anticancer Actions: Insights from R

  2026-05-04

  This comprehensive review details catalpol’s ability to combat cancer progression through modulation of apoptosis, signaling pathways, and metastasis-related mechanisms. By synthesizing preclinical evidence across multiple cancer types, the paper highlights catalpol’s potential as a research tool for understanding and targeting malignant processes.

• Axitinib (AG 013736): Precise VEGFR Inhibition in Cancer Bio

  2026-05-03

  Axitinib (AG 013736) is a highly selective, orally bioavailable VEGFR tyrosine kinase inhibitor. It demonstrates nanomolar potency against VEGFR1/2/3 and robust selectivity in angiogenesis inhibition assays. This dossier provides verifiable evidence for its integration in cancer biology research workflows.

• α-Amanitin: Precision Tool for RNA Polymerase II Assays

  2026-05-02

  α-Amanitin’s unrivaled specificity for RNA polymerase II makes it indispensable for dissecting transcriptional regulation and gene expression pathways in both developmental and disease models. This guide details experimental workflows, troubleshooting, and the latest mechanistic insights—empowering researchers to optimize results using APExBIO’s high-purity α-Amanitin.

• Foretinib (GSK1363089): Multikinase Inhibition in Cancer Res

  2026-05-02

  Foretinib (GSK1363089) is a potent ATP-competitive inhibitor targeting VEGFRs and MET, offering robust suppression of tumor cell proliferation and metastasis. Its low nanomolar IC50 values and efficacy in multiple cancer models position it as a key tool for translational oncology research.

• Poly (I:C): Synthetic dsRNA Analog for Advanced Immune Activ

  2026-05-01

  Poly (I:C), the benchmark synthetic double-stranded RNA analog, enables precise stimulation of innate immune pathways and dendritic cell maturation for cutting-edge immunology and antiviral research. This guide details practical workflows, experimental enhancements, and troubleshooting strategies to maximize its impact in both basic and translational applications.

16540 records 1/1103 page Next 12345 下5页 Last page